Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

  • Protocol
  • Intervention

Authors

  • Mari Jeeva Sankar,

    Corresponding author
    1. ICMR Center for Advanced Research in Newborn Health, WHO Collaborating Centre for Training and Research in Newborn Care, All India Institute of Medical Sciences, Department of Pediatrics, New Delhi, India
    • Mari Jeeva Sankar, Department of Pediatrics, ICMR Center for Advanced Research in Newborn Health, WHO Collaborating Centre for Training and Research in Newborn Care, All India Institute of Medical Sciences, New Delhi, India. jeevasankar@gmail.com.

    Search for more papers by this author
  • Jhuma Sankar,

    1. Dr. Ram Manohar Lohia Hospital, Department of Pediatrics, PGIMER, New Delhi, India
    Search for more papers by this author
  • Vishnu Bhat,

    1. JIPMER, Department of Pediatrics, Pondicherry, Pondicherry, India
    Search for more papers by this author
  • Renuka Srinivasan

    1. JIPMER, Department of Ophthalmology, Pondicherry, Pondicherry, India
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the efficacy and safety of anti-VEGF drugs when used either as monotherapy (i.e. without concomitant cryotherapy or laser photocoagulation) (Objective 1) or in combination with planned cryo/laser therapy (Objective 2) in preterm neonates with ROP.